Company Name
Guangdong Jiabo Pharmaceutical Co., Ltd.
Year of Establishment
2003
Company Introduction
Guangdong Jiabo Pharmaceutical Co., Ltd. (hereinafter abbreviated as Jiabo Pharm) has a R & D team composed of professional researchers, doctors and masters now. Over recent years, the R&D center has actively carried out proprietary R&D projects, participated in and undertaken a number of national, provincial and municipal science & technology projects, owned a number of authorized invention patents and utility model patents, and won the honorary title of China Patent Award. Relying on the R&D center, the company actively carries out cooperation with foreign parties, and has successively established technology platforms such as the Production, Study & Research Base of Sun Yat Sen University, Guangdong Intravenous Fat Emulsion Engineering Technology Research Center and Guangdong Postdoctoral Innovation Practice Base, so as to improve the R&D and innovation ability of the company and push the high-quality development of the company.
The company, with perfect product layout, has many GMP production lines such as small volume parenterals, large volume parenterals, sterilized small volume parenteral, soft bag line and API, as well as a production line in line with EU standard (to be certified), which can meet the industrialized production of various complex injections. At present, the R&D pipeline reserve is sufficient, many products with market potentiality are to be launched, and the production technology and related quality control technology of complex injections such as liposome and fat emulsion are advanced over other domestic manufacturers.
Main Competitive Advantages
Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Reputation,Quality Service,
Other Competitive Advantages
Jiabo technology platform is committed to the research in the field of perioperative anesthesia and drug delivery system for injection. Various of R&D platforms, including Qingyuan Engineering Technology R&D Center for Microemulsion Delivery System, Guangdong Engineering and Technology Research Center for Intravenous Fat Emulsion, Guangdong Postdoctoral Innovation Practice Base, Guangdong Enterprise Technology Center, Guangdong Doctoral Workstation and National Postdoctoral Workstation (substation) , have been successively established.
With a R&D team of up to 90 personnel, Jiabo lays a good foundation for scientific research and innovation by introducing Qingyuan research and innovation team for intravenous fat emulsion, Yangfan plan for core technology of lipid-based drug delivery system and industrialization team, as well as Dr. Cai Tingwei who returned from overseas and graduated from Ohio State University with his major in pharmaceutical chemistry.
Patents and Copyright
In recent years, Jiabo technology platform has made great achievements in research and development projects, approved manufacturing licenses and patents. In 2012, Jiabo was entrusted by regulatory authority to draft the national quality standard of Propofol injection. The major products, such as Propofol Injectable Emulsion, Propofol Medium and Long Chain Fat Emulsion Injection, Ropivacaine Hydrochloride Injection and Methoxamine Hydrochloride Injection, have been accredited as high&new technology product. Jiabo has won the 16th China Patent Excellence Award, the first prize of Qingyuan Science&Technology Progress Award, the third prize of Guangdong Science&Technology Award, the first prize of “Innovative Qingyuan” science and technology award in 2021 and Guangdong "May Day Labor Award" in 2021.
Milestone
Sep. 2003
The company was founded.
Nov. 2005
Begun to put into production and approved by GMP.
Nov. 2009
Qualified as the high-tech enterprise of Guangdong Province.
Sep. 2011
Invited by NMPA to draft the specification of Propofol Injection.
Nov. 4th, 2016
Propofol Injection was changed as Propofol Injectable Emulsion.
Nov. 2014
Awarded the China Excellent Patent Award.
Nov. 2015
Awarded the excellent brand of neuropsychotic products of China chemical&pharmaceutical industry.
Mar. 2016
Awarded Qingyuan Science&Technology Progress Award, the first prize.
Feb. 2017
Awarded Guangdong Science&Technology Award, the third prize.
Nov. 2018
Awarded as Chinese technological&innovative enterprise with the most growth potential.
DISHILE, Propofol Medium and Long Chain Fat Emulsion Injection, awarded as the most innovative product of China.
Apr. 2019
Approved by Intellectual Property Management System (IPMS).
Aug. 2019
Awarded as the most investing value enterprise (unlisted) of Chinese pharmaceutical industry.
Aug. 2020
Awarded as enterprise with the most growth potential of Chinese pharmaceutical industry.